A depot injection, also known as a long-acting injectable (LAI), is a term for an injection formulation of a medication which releases slowly over time to permit less frequent administration of a medication. They are designed to increase medication adherence and consistency, especially in patients who commonly forget to take their medicine. Depot injections can be created by modifying the drug molecule itself, as in the case of prodrugs, or by modifying the way it is administered, as in the case of oil/lipid suspensions. Depot injections can have a duration of action of one month or greater and are available for many types of drugs, including antipsychotics and hormones.
Purpose
editDepot injections provide longer duration drug action through slow absorption into the bloodstream. They are usually administered in the muscle, into the skin, or under the skin. The injected medication slowly releases the medication into the bloodstream. It may be used in patients who forget to take their medication; some doctors and patients consider the use of a depot injection to be coercion, and are opposed to their use for that reason.[1]
Mechanism
editDrugs may be modified to be slowly activated by the body, or be absorbed slowly by the body. Many are dissolved in an organic oil, as the compound is lipophilic due to the addition of functional groups to provide slow action. An example of this is adding a functional group such as decanoate.[2] The combination of an oil base and modification to decrease metabolic activation prevent medications from being fully released.[2][3] This can result in length of activity of 2–4 weeks or more.[2][3]
The alteration of the pharmacokinetics of the drug (the absorption and activation) does not change the side effect profile of the medication; thus, atypical antipsychotics are still preferred over typical antipsychotics.[3]
Discovery
editThe first long-acting (depot) injections were antipsychotics fluphenazine and haloperidol.[2] The concept of a depot injection arose before 1950, and originally was used to describe antibiotic injections that lasted longer to allow for less frequent administration.[4]
Pharmacokinetics
editMost commonly, depot injections are designed to have a duration of 2–4 weeks of action,[5] however the pharmacokinetics of a specific formulation vary. Absorption and metabolism can both be affected by modifying the drug itself (for example, by attaching a functional group) or by the formulation of the product (examples are oil or microsphere preparations).[5] Repeated administration of depot injections can lead to a half life over one month (as in some preparations of fluphenazine), but this can be variable in different patients.[6]
Hormonal depot injections of estradiol can last anywhere from one week to over one month.[7] Medroxyprogesterone acetate is available as a depot injection which is injected once every three months to provide continuous hormonal contraception and releases for up to nine months after injection.[8]
Availability
editMany medications are available as depot injections, including many typical and atypical antipsychotics,[9] as well as some hormonal medications and medication for opioid use disorder.[10][11][1] Depot injections of antipsychotics are used to improve historically low adherence in patients with diseases such as schizophrenia.[9] Different products may be administered or implanted either by a doctor or nurse, while some are designed to be administered by the patient themselves.[12] Self-administered depot injections are used to increase healthcare access and decrease the need to visit the doctor as frequently, especially in low and middle income countries.[12]
Insulin may also be considered a depot injection depending on formulation. Insulin glargine, for example, is designed to precipitate after injection so it can be slowly absorbed by the body over a longer period than regular insulin would be.[13] Depot injections of insulins have been studied to better replicate the body's natural basal rate of insulin production, and which can be activated by light to control the release of insulin from the injected depot.[14]
See also
editReferences
edit- ^ a b Lindenmayer, Jean-Pierre; Glick, Ira D.; Talreja, Hiteshkumar; Underriner, Michael (July 2020). "Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia". Journal of Clinical Psychopharmacology. 40 (4): 346–349. doi:10.1097/JCP.0000000000001225. PMID 32639287. S2CID 220412843.
- ^ a b c d Kennedy, WK (2012). "When and how to use long-acting injectable antipsychotics". Current Psychiatry. 11 (8): 40–43.
- ^ a b c Carpenter, J; Wong, KK (2018). "Long-acting injectable antipsychotics: What to do about missed doses". Current Psychiatry. 17 (7): 10–12, 14–19, 56.
- ^ PRIEST, WS; SMITH, JM (1949). "Depot penicillin in the treatment of bacterial endocarditis". Quarterly Bulletin. Northwestern University (Evanston, Ill.). Medical School. 23 (1): 90–92. PMC 3802847. PMID 18109791.
- ^ a b Wright, Jeremy C.; Burgess, Diane J. (29 January 2012). Long acting injections and implants. Springer. p. 114. ISBN 978-1-4614-0554-2.
- ^ Curry, SH; Whelpton, R; Schepper, PJ; Vranckx, S; Schiff, AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–331. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
- ^ Driowo, M.A.; Landgren, B.-M.; Stenström, B.; Diczfalusy, E. (April 1980). "A comparison of the pharmacokinetic properties of three estradiol esters". Contraception. 21 (4): 415–424. doi:10.1016/S0010-7824(80)80018-7. PMID 7389356.
- ^ Mishell DR, Jr (May 1996). "Pharmacokinetics of depot medroxyprogesterone acetate contraception". The Journal of Reproductive Medicine. 41 (5 Suppl): 381–90. PMID 8725700.
- ^ a b Meyer, Jonathan M. (19 January 2018). "Converting oral to long-acting injectable antipsychotics: a guide for the perplexed". CNS Spectrums. 22 (S1): 14–28. doi:10.1017/S1092852917000840. PMID 29350127. S2CID 9835921.
- ^ Burke, Holly M.; Chen, Mario; Packer, Catherine; Fuchs, Rachael; Ngwira, Bagrey (May 2020). "Young Women's Experiences With Subcutaneous Depot Medroxyprogesterone Acetate: A Secondary Analysis of a One-Year Randomized Trial in Malawi". Journal of Adolescent Health. 67 (5): 700–707. doi:10.1016/j.jadohealth.2020.03.038. PMID 32389457.
- ^ Zhou, Jia; Walker, Jennifer; Ackermann, Rose; Olsen, Karl; Hong, Justin K. Y.; Wang, Yan; Schwendeman, Steven P. (19 February 2020). "Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide". Molecular Pharmaceutics. 17 (5): 1502–1515. doi:10.1021/acs.molpharmaceut.9b01188. PMID 32074448. S2CID 211213131.
- ^ a b Burke, Holly M.; Packer, Catherine; Buluzi, Mercy; Healy, Elise; Ngwira, Bagrey (November 2018). "Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi". Contraception. 98 (5): 405–410. doi:10.1016/j.contraception.2018.02.011. PMID 29706227.
- ^ Lindauer, Klaus; Becker, Reinhard (1 January 2019). "Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL". International Journal of Clinical Pharmacology and Therapeutics. 57 (1): 1–10. doi:10.5414/CP203269. PMC 6298133. PMID 30369394.
- ^ Jain, Piyush K.; Karunakaran, Dipu; Friedman, Simon H. (28 January 2013). "Construction of a Photoactivated Insulin Depot". Angewandte Chemie International Edition. 52 (5): 1404–1409. doi:10.1002/anie.201207264. PMID 23208858.